The run rate is probably much closer to $750m/$800m at this point.
Cowen’s Eric Schmidt just wrote a “quick take” report estimating that NVS’ 4Q10 end-user Lovenox sales were $200-225M, which is consistent with my run-rate estimate in #msg-59286675. FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”